Sareum Holdings ( (GB:SAR) ) has provided an update.
Sareum Holdings PLC announced that its Executive Chairman, Dr. Stephen Parker, purchased 84,033 ordinary shares at an average price of 11.9 pence per share, increasing his total direct and indirect holdings to 405,045 shares, which represents approximately 0.30% of the company’s issued share capital. This transaction, conducted on the London Stock Exchange, reflects Dr. Parker’s confidence in the company’s strategic direction and potential growth, potentially influencing investor sentiment positively.
More about Sareum Holdings
Sareum Holdings PLC is a biotechnology company based in Cambridge, UK, focused on developing next-generation kinase inhibitors for autoimmune diseases and cancer. The company is advancing small molecules that modify the activity of the JAK kinase family, with lead candidates SDC-1801 and SDC-1802 targeting autoimmune diseases and cancer immunotherapy, respectively. Sareum has also acquired the license for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor.
YTD Price Performance: -51.02%
Average Trading Volume: 394,147
Technical Sentiment Signal: Buy
Current Market Cap: £16.02M
For an in-depth examination of SAR stock, go to TipRanks’ Stock Analysis page.